The EMA has published an overview of 2017 developments, which includes key recommendations regarding new medicines and safety advice issued during the year. EMA recommended 92 medicines for marketing authorization. Of these, 35 had a new active substance not previously authorized in the EU.
INTERNATIONAL PHARMACEUTICAL QUALITY
Inside the Global Regulatory Dialogue
